SEC Form 4 · accession 0001104659-18-018390
Amphastar Pharmaceuticals, Inc. · AMPH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Richard K Prins
Director
Period of report
Mar 15, 2018
Accepted (ET)
Mar 16, 2018 · 6:19 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001297184
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 15, 2018 | M | 16,598 | $14.66 | A | 45,442 | D | |
| Common StockF1 | Mar 15, 2018 | S | 16,598 | $19.9011 | D | 28,844 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $14.66 | Mar 15, 2018 | M | 16,598 | D | — | Dec 20, 2018 | Common Stock | 16,598 | 20,000 | D |
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.77 to $20.18, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
- F2Shares subject to the option are fully vested and immediately exercisable.
Remarks
Exhibit 24 - Power of Attorney